Filter News
Area of Research
News Topics
- (-) Biomedical (2)
- (-) Cybersecurity (1)
- (-) Frontier (1)
- (-) Physics (2)
- 3-D Printing/Advanced Manufacturing (2)
- Advanced Reactors (1)
- Artificial Intelligence (2)
- Bioenergy (3)
- Biology (7)
- Biotechnology (1)
- Buildings (1)
- Chemical Sciences (4)
- Climate Change (1)
- Computer Science (1)
- Coronavirus (1)
- Critical Materials (1)
- Decarbonization (2)
- Energy Storage (6)
- Environment (6)
- Grid (1)
- Materials (6)
- Materials Science (3)
- Microscopy (1)
- Nanotechnology (1)
- National Security (1)
- Neutron Science (12)
- Nuclear Energy (1)
- Partnerships (3)
- Quantum Science (1)
- Security (2)
- Space Exploration (1)
- Sustainable Energy (2)
- Transformational Challenge Reactor (1)
- Transportation (1)
Media Contacts
Paul Langan will join ORNL in the spring as associate laboratory director for the Biological and Environmental Systems Science Directorate.
To solve a long-standing puzzle about how long a neutron can “live” outside an atomic nucleus, physicists entertained a wild but testable theory positing the existence of a right-handed version of our left-handed universe.
ORNL scientists will present new technologies available for licensing during the annual Technology Innovation Showcase. The event is 9 a.m. to 3 p.m. Thursday, June 16, at the Manufacturing Demonstration Facility at ORNL’s Hardin Valley campus.
Three ORNL scientists have been elected fellows of the American Association for the Advancement of Science, or AAAS, the world’s largest general scientific society and publisher of the Science family of journals.
An ORNL-led team's observation of certain crystalline ice phases challenges accepted theories about super-cooled water and non-crystalline ice. Their findings, reported in the journal Nature, will also lead to better understanding of ice and its various phases found on other planets, moons and elsewhere in space.
OAK RIDGE, Tenn., March 20, 2019—Direct observations of the structure and catalytic mechanism of a prototypical kinase enzyme—protein kinase A or PKA—will provide researchers and drug developers with significantly enhanced abilities to understand and treat fatal diseases and neurological disorders such as cancer, diabetes, and cystic fibrosis.